Latest & greatest articles for Lamivudine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Lamivudine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Lamivudine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Lamivudine

41. Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials

Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials Rudin D CRD summary Lamivudine in combination (...) with PEGylated interferon had better outcomes than lamivudine monotherapy, but not PEGylated interferon monotherapy. Lamivudine in combination with conventional interferon had better outcomes than lamivudine monotherapy or conventional interferon monotherapy. The possibility of reviewer error or bias and a conclusion that extended beyond the data presented mean that the conclusions should be treated with some caution. Authors' objectives To assess the effectiveness of lamivudine and interferon compared

2007 DARE.

42. Telbivudine versus lamivudine in patients with chronic hepatitis B. Full Text available with Trip Pro

Telbivudine versus lamivudine in patients with chronic hepatitis B. Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B.In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamivudine once daily. The primary efficacy end point was noninferiority of telbivudine to lamivudine for therapeutic response (i.e., a reduction in serum HBV (...) DNA levels to fewer than 5 log10 copies per milliliter, along with loss of hepatitis B e antigen [HBeAg] or normalization of alanine aminotransferase levels). Secondary efficacy measures included histologic response, changes in serum HBV DNA levels, and HBeAg responses.At week 52, a significantly higher proportion of HBeAg-positive patients receiving telbivudine than of those receiving lamivudine had a therapeutic response (75.3% vs. 67.0%, P=0.005) or a histologic response (64.7% vs. 56.3%, P

2007 NEJM Controlled trial quality: predicted high

43. Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan

Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan Sullivan S D, Veenstra D L, Chen P (...) J, Chang T T, Chuang W L, Tsai C, Patel K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective of the study was to assess the cost-effectiveness of peginterferon alpha-2a, compared with lamivudine, for the treatment

2007 NHS Economic Evaluation Database.

44. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom

Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

45. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B

Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B Veenstra D L, Sullivan S D, Clarke L, Iloeje U H, Tafesse E, Di Bisceglie A, Kowdley K V, Gish R G Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of entecavir versus lamivudine (plus adefovir as salvage therapy) for the treatment of hepatitis B e antigen positive chronic hepatitis B. Entecavir was a cost-effective alternative to lamivudine with adefovir

2007 NHS Economic Evaluation Database.

46. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. (Abstract)

Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. A favourable regimen for people infected with HIV/AIDS is one that provides optimal efficacy, durability of antiretroviral activity, tolerability, and has low adverse effects and drug-drug interactions. The combination of the non-nucleoside reverse transcriptase inhibitor nevirapine (NVP), and two nucleoside reverse transcriptase inhibitors, stavudine (d4T) and lamivudine (3TC), is widely (...) used as first-line therapy, especially in low-resource countries. Analysis of the efficacy, durability and tolerability of the regimen is thus important to clinicians, consumers and policy-makers living in both rich and poor countries.To examine the efficacy of the stavudine, lamivudine and nevirapine regimen for the treatment of HIV infection and AIDS in adults.We used the comprehensive search strategy developed specifically by the Cochrane HIV/AIDS Review Group to identify HIV/AIDS randomised

2006 Cochrane

47. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Full Text available with Trip Pro

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere.We conducted an open-label, noninferiority study involving 517 patients with HIV infection who had not previously received antiretroviral therapy and who were randomly assigned to receive either a regimen of tenofovir (...) disoproxil fumarate (DF), emtricitabine, and efavirenz once daily (tenofovir-emtricitabine group) or a regimen of fixed-dose zidovudine and lamivudine twice daily plus efavirenz once daily (zidovudine-lamivudine group). The primary end point was the proportion of patients without baseline resistance to efavirenz in whom the HIV RNA level was less than 400 copies per milliliter at week 48 of the study.Through week 48, significantly more patients in the tenofovir-emtricitabine group reached and maintained

2006 NEJM Controlled trial quality: uncertain

48. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. Full Text available with Trip Pro

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. Entecavir is a potent and selective guanosine analogue with significant activity against hepatitis B virus (HBV).In this phase 3, double-blind trial, we randomly assigned 715 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had not previously received a nucleoside analogue to receive either 0.5 mg of entecavir or 100 mg of lamivudine once daily for a minimum of 52 weeks. The primary (...) efficacy end point was histologic improvement (a decrease by at least two points in the Knodell necroinflammatory score, without worsening of fibrosis) at week 48. Secondary end points included a reduction in the serum HBV DNA level, HBeAg loss and seroconversion, and normalization of the alanine aminotransferase level.Histologic improvement after 48 weeks occurred in 226 of 314 patients in the entecavir group (72 percent) and 195 of 314 patients in the lamivudine group (62 percent, P=0.009). More

2006 NEJM Controlled trial quality: predicted high

49. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. Full Text available with Trip Pro

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.In this phase 3, double-blind trial, we randomly assigned 648 patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue to receive 0.5 mg of entecavir or 100 mg of lamivudine once daily (...) for a minimum of 52 weeks. The primary efficacy end point was histologic improvement (a decrease by at least two points in the Knodell necroinflammatory score, without worsening of fibrosis).Histologic improvement after 48 weeks of treatment occurred in 208 of 296 patients in the entecavir group who had adequate baseline liver-biopsy specimens that could be evaluated (70 percent), as compared with 174 of 287 such patients in the lamivudine group (61 percent, P=0.01). More patients in the entecavir group

2006 NEJM Controlled trial quality: predicted high

50. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. (Abstract)

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety to lopinavir-ritonavir when each is combined with two nucleoside reverse transcriptase inhibitors. We compared the two treatments (...) directly in antiretroviral-naive patients.This open-label, non-inferiority study included 878 antiretroviral-naive, HIV-1-infected patients randomised to receive either fosamprenavir-ritonavir 700 mg/100 mg twice daily or lopinavir-ritonavir 400 mg/100 mg twice daily, each with the co-formulation of abacavir-lamivudine 600 mg/300 mg once daily. Primary endpoints were proportion of patients achieving HIV-1 RNA less than 400 copies per mL at week 48 and treatment discontinuations because of an adverse

2006 Lancet Controlled trial quality: uncertain

51. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B

Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B Buti M, Casado M A, Calleja J L, Salmeron J, Aguilar J, Rueda M, Esteban R Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared lamivudine and adefovir dipivoxil in the treatment of patients with hepatitis B 'e' antigen (HbeAg)-negative chronic hepatitis B (CHB). Both drugs involved a daily oral dose of 100 mg. Type

2006 NHS Economic Evaluation Database.

52. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. (Abstract)

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained response.307 HBeAg-positive patients with chronic hepatitis B were assigned combination therapy (100 microg/week pegylated interferon alfa-2b and 100 mg/day (...) lamivudine) or monotherapy (100 microg/week pegylated interferon alfa-2b and placebo) for 52 weeks. During weeks 32-52 the pegylated interferon dose was 50 microg/week in both treatment groups. The analyses were based on the modified intention-to-treat population after exclusion of 24 patients from one centre withdrawn for misconduct, ten who lost HBeAg before the study start, and seven who received no study medication. All included patients were followed up for 26 weeks after treatment.49 (36%) of 136

2005 Lancet Controlled trial quality: uncertain

53. Combivir - lamivudine / zidovudine

Combivir - lamivudine / zidovudine 1/11 ?EMEA 2005 SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Combivir. This scientific discussion has been updated until 30 July 2005. For information on changes after this date please refer to module 8b. 1. Introduction Current available therapy options for the treatment of Human Immunodeficiency Virus (HIV) infection comprises four different mechanistic classes of compounds: nucleoside/nucleotide analogue (...) to be the standard of care of HIV infected patients. These therapeutic regimens result however in a great number of daily doses of tablets/capsules. Combivir was the first fixed dose combination containing two known antiretroviral agents belonging to the RT inhibitors class. This medicinal product containing 150 mg of lamivudine and 300 mg zidovudine has been developed as an oral therapy (tablet) for the treatment of HIV-1 infection in adults. Individual formulations of lamivudine (150 mg tablets) and zidovudine

2005 European Medicines Agency - EPARs

54. abacavir/lamivudine

abacavir/lamivudine CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ABACAVIR/LAMIVUDINE (Kivexa™ - GlaxoSmithKline) Description: Kivexa™ is a fixed dose combination of abacavir and lamivudine, two nucleoside reverse transcriptase inhibitors (NRTIs), that is indicated in antiretroviral therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults. Dosage Form: Tablet containing abacavir 600 mg and lamivudine 300 mg. Recommendation: The Canadian Expert Drug (...) Advisory Committee (CEDAC) recommends that Kivexa™ be listed in a similar manner as drug plans list other NRTIs for treatment of HIV infected adults. Reasons for the recommendation: 1. Two unpublished open label randomized controlled trials compared the fixed dose combination of abacavir/lamivudine (600mg/300mg) to either: - abacavir 300mg bid and lamivudine 300 mg once daily or - abacavir 300 mg bid and lamivudine 150 mg bid. These regimens were further combined with either a non-nucleoside reverse

2005 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

55. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. Full Text available with Trip Pro

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and lamivudine alone for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.A total of 814 patients with HBeAg-positive chronic hepatitis B received (...) either peginterferon alfa-2a (180 microg once weekly) plus oral placebo, peginterferon alfa-2a plus lamivudine (100 mg daily), or lamivudine alone. The majority of patients in the study were Asian (87 percent). Most patients were infected with hepatitis B virus (HBV) genotype B or C. Patients were treated for 48 weeks and followed for an additional 24 weeks.After 24 weeks of follow-up, significantly more patients who received peginterferon alfa-2a monotherapy or peginterferon alfa-2a plus lamivudine

2005 NEJM Controlled trial quality: uncertain

56. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. Full Text available with Trip Pro

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications.We compared the efficacy and safety of peginterferon alfa-2a (...) (180 microg once weekly) plus placebo, peginterferon alfa-2a plus lamivudine (100 mg daily), and lamivudine alone in 177, 179, and 181 patients with HBeAg-negative chronic hepatitis B, respectively. Patients were treated for 48 weeks and followed for an additional 24 weeks.After 24 weeks of follow-up, the percentage of patients with normalization of alanine aminotransferase levels or hepatitis B virus (HBV) DNA levels below 20,000 copies per milliliter was significantly higher with peginterferon

2004 NEJM Controlled trial quality: uncertain

57. Lamivudine for patients with chronic hepatitis B and advanced liver disease. (Abstract)

Lamivudine for patients with chronic hepatitis B and advanced liver disease. The effectiveness of antiviral therapy in preventing disease progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown.Patients with chronic hepatitis B who had histologically confirmed cirrhosis or advanced fibrosis were randomly assigned in a 2:1 ratio to receive lamivudine (100 mg per day) or placebo for a maximum of five years. Of 651 patients, 436 were assigned to receive (...) lamivudine and 215 to receive placebo. The primary end point was time to disease progression, defined by hepatic decompensation, hepatocellular carcinoma, spontaneous bacterial peritonitis, bleeding gastroesophageal varices, or death related to liver disease. An independent data and safety monitoring board monitored the progress of the study and performed interim analyses of the data.We randomly assigned 651 patients (98 percent Asian and 85 percent male) to receive lamivudine or placebo. The study

2004 NEJM Controlled trial quality: predicted high

58. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. (Abstract)

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. The 2NN Study was a randomised comparison of the non-nucleoside reverse-transcriptase inhibitors (NNRTI) nevirapine and efavirenz.In this multicentre, open-label, randomised trial, 1216 antiretroviral-therapy-naive patients were assigned nevirapine 400 mg once daily, nevirapine 200 mg twice daily, efavirenz 600 (...) mg once daily, or nevirapine (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine, for 48 weeks. The primary endpoint was the proportion of patients with treatment failure (less than 1 log(10) decline in plasma HIV-1 RNA in the first 12 weeks or two consecutive measurements of more than 50 copies per mL from week 24 onwards, disease progression [new Centers for Disease Control and Prevention grade C event or death], or change of allocated treatment). Analyses were

2004 Lancet Controlled trial quality: predicted high

59. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials

Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P CRD summary This review evaluated (...) the efficacy and safety of lamivudine for the treatment of hepatitis B following renal transplantation. The authors found that rates of virological and biochemical response to lamivudine were high and the drug was well tolerated, but lamivudine resistance was frequent after prolonged therapy. The conclusions are based on evidence from uncontrolled studies and, therefore, may not be reliable. Authors' objectives To evaluate the safety and efficacy of initial lamivudine monotherapy in renal transplant

2004 DARE.

60. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. (Abstract)

Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Patients who have not received previous antiretroviral treatment (ART) have a high failure rate on the combination treatment of abacavir, lamivudine, and tenovir. We assessed the virological failure rate in eight patients with HIV-1 who switched to this combination after having complete virological suppression from their previous long-term ART (median 8.0 months, range

2003 Lancet Controlled trial quality: uncertain